Close Menu

NEW YORK (GenomeWeb) – Guardant Health today announced that it has partnered with the National Cancer Institute-funded SWOG cancer research consortium to identify mechanisms of resistance and future treatment options in non-small cell lung cancer patients.

The study, called SWOG-1403, will use Guardant's circulating tumor DNA test, Guardant 360, to examine whether combination EGFR blockade using cetuximab and afatinib is superior to afatinib alone as a frontline treatment for 600 patients with newly diagnosed EGFR-mutant NSCLC.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

A new paper says an effort to introduce gene drives into mosquitos altered the genetic makeup of the local mosquitos, but the company behind the project says the paper is flawed.

Virginia's Department of Forensic Science is offering attorneys a course on DNA testing, the Virginian-Pilot reports.

Researchers examine changes in the genomes of emmer wheat populations where the climate has warmed, the BBC reports.

In Cell this week: microinjection of CRISPR-Cas9 enables targeted mutations in Anolis, melanoma proteomic profiling, and more.